Published in Hum Vaccin Immunother on January 01, 2012
A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children | NCT01218308
Study of Quadrivalent Influenza Vaccine Among Adults | NCT01218646
A Study of Influenza Virus Vaccines in Children and Adults | NCT00988143
Study of Quadrivalent Influenza Vaccine Among Children | NCT01240746
Highly conserved protective epitopes on influenza B viruses. Science (2012) 3.47
Broadly neutralizing antibodies against influenza viruses. Antiviral Res (2013) 1.29
A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis (2013) 1.06
4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany. BMC Infect Dis (2014) 1.05
Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011-12 season. PLoS One (2013) 1.00
Animal models for influenza viruses: implications for universal vaccine development. Pathogens (2014) 0.99
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis (2013) 0.96
Advances in pediatric pharmacology, therapeutics, and toxicology. Adv Pediatr (2014) 0.96
Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom. BMC Infect Dis (2015) 0.94
Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. Antimicrob Agents Chemother (2014) 0.88
Molecular epidemiology and phylogenetic analyses of influenza B virus in Thailand during 2010 to 2014. PLoS One (2015) 0.88
An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model. PLoS One (2015) 0.87
Universal influenza B virus genomic amplification facilitates sequencing, diagnostics, and reverse genetics. J Clin Microbiol (2014) 0.87
Economic burden of seasonal influenza B in France during winter 2010-2011. BMC Public Health (2014) 0.87
Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis (2013) 0.85
A comprehensive review of the epidemiology and disease burden of Influenza B in 9 European countries. Hum Vaccin Immunother (2016) 0.83
Ten influenza seasons in France: distribution and timing of influenza A and B circulation, 2003-2013. BMC Infect Dis (2015) 0.82
Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium. J Virol (2015) 0.81
Ten years (2004-2014) of influenza surveillance in Northern Italy. Hum Vaccin Immunother (2014) 0.81
Morphology of influenza B/Lee/40 determined by cryo-electron microscopy. PLoS One (2014) 0.81
Influenza vaccines: unmet needs and recent developments. Infect Chemother (2013) 0.81
Comparison of the epidemiology of laboratory-confirmed influenza A and influenza B cases in Manitoba, Canada. BMC Public Health (2015) 0.80
The Molecular Epidemiology and Evolutionary Dynamics of Influenza B Virus in Two Italian Regions during 2010-2015: The Experience of Sicily and Liguria. Int J Mol Sci (2016) 0.80
Surveillance of influenza viruses in the post-pandemic era (2010-2012) in Northern Italy. Hum Vaccin Immunother (2013) 0.80
Prospects of HA-based universal influenza vaccine. Biomed Res Int (2015) 0.79
Influenza B vaccine lineage selection-An optimized trivalent vaccine. Vaccine (2016) 0.79
An overview of the regulation of influenza vaccines in the United States. Influenza Other Respir Viruses (2016) 0.79
Genetic characterisation of influenza B viruses detected in Singapore, 2004 to 2009. BMC Res Notes (2014) 0.78
Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage. J Gen Virol (2015) 0.78
Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden. J Prev Med Hyg (2016) 0.78
Evaluating the case for trivalent or quadrivalent influenza vaccines. Hum Vaccin Immunother (2016) 0.78
Inactivated influenza virus vaccines: the future of TIV and QIV. Curr Opin Virol (2017) 0.77
Epidemiology of influenza B in Australia: 2001-2014 influenza seasons. Influenza Other Respir Viruses (2016) 0.77
Identification of conserved RNA secondary structures at influenza B and C splice sites reveals similarities and differences between influenza A, B, and C. BMC Res Notes (2014) 0.77
Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach. Hum Vaccin Immunother (2016) 0.77
The impact of influenza virus B in Italy: myth or reality? J Prev Med Hyg (2016) 0.76
Striking Similarities in the Presentation and Duration of Illness of Influenza A and B in the Community: A Study Based on Sentinel Surveillance Networks in France and Turkey, 2010-2012. PLoS One (2015) 0.75
Introduction of a quadrivalent influenza vaccine in Italy: a budget impact analysis. J Prev Med Hyg (2016) 0.75
Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines. Hum Vaccin Immunother (2016) 0.75
Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study. Hum Vaccin Immunother (2016) 0.75
The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland. Pharmacoeconomics (2016) 0.75
Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies. PLoS One (2017) 0.75
Detection of influenza B lineages from 2001 to 2013 in a tertiary hospital in the city of São Paulo, Brazil. Mem Inst Oswaldo Cruz (2015) 0.75
Epidemiological and Virological Characterization of Influenza B Virus Infections. PLoS One (2016) 0.75
Oral Modeling of an Adenovirus-Based Quadrivalent Influenza Vaccine in Ferrets and Mice. Infect Dis Ther (2016) 0.75
Clinical Features of Influenza and Acute Respiratory Illness in Older Adults at Least 50 Years of Age in an Outpatient Setting in the Republic of Korea: a Prospective, Observational, Cohort Study. J Korean Med Sci (2017) 0.75
Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine. Virol J (2015) 0.75
A novel molecular test for influenza B virus detection and lineage differentiation. J Med Virol (2014) 0.75
Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia. BMC Public Health (2016) 0.75
Development of high-yield influenza B virus vaccine viruses. Proc Natl Acad Sci U S A (2016) 0.75
Quadrivalent influenza vaccine in the United States. Hum Vaccin Immunother (2013) 0.75
Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America. Hum Vaccin Immunother (2017) 0.75
Competitive Fitness of Influenza B Viruses Possessing E119A and H274Y Neuraminidase Inhibitor Resistance-Associated Substitutions in Ferrets. PLoS One (2016) 0.75
Influenza B virus has global ordered RNA structure in (+) and (-) strands but relatively less stable predicted RNA folding free energy than allowed by the encoded protein sequence. BMC Res Notes (2013) 0.75
Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe. Hum Vaccin Immunother (2016) 0.75
Neurologic Complications of Influenza B Virus Infection in Adults, Romania. Emerg Infect Dis (2017) 0.75
Assessment of potential public health impact of a quadrivalent inactivated influenza vaccine in Thailand. Influenza Other Respir Viruses (2016) 0.75
Rules of co-occurring mutations characterize the antigenic evolution of human influenza A/H3N2, A/H1N1 and B viruses. BMC Med Genomics (2016) 0.75
Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 years of age and older. Hum Vaccin Immunother (2017) 0.75
US Healthcare Costs Attributable to Type A and Type B Influenza. Hum Vaccin Immunother (2017) 0.75
Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 31.71
Influenza-associated hospitalizations in the United States. JAMA (2004) 18.23
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep (2010) 10.59
Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology (1990) 4.71
Monitoring the impact of influenza by age: emergency department fever and respiratory complaint surveillance in New York City. PLoS Med (2007) 3.48
Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine (2012) 2.67
Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis (2010) 2.36
Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis (2010) 2.16
Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine (2009) 2.11
Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine (2009) 1.99
The evolutionary dynamics of human influenza B virus. J Mol Evol (2008) 1.84
Influenza A and B virus infections in children. Clin Infect Dis (2003) 1.78
Retracted Burden of influenza in healthy children and their households. Arch Dis Child (2004) 1.63
Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands. Clin Vaccine Immunol (2011) 1.57
Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis (2009) 1.47
Clinical manifestations and socio-economic impact of influenza among healthy children in the community. J Infect (2011) 1.40
A global pandemic influenza vaccine action plan. Vaccine (2006) 1.31
Long time trends in influenza-like illness and associated determinants in The Netherlands. Epidemiol Infect (2008) 1.30
Medically attended pediatric influenza during the resurgence of the Victoria lineage of influenza B virus. Int J Infect Dis (2006) 1.29
Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004-2005 through 2007-2008. Influenza Other Respir Viruses (2011) 1.22
High proportion of influenza B characterises the 2008 influenza season in Victoria. Commun Dis Intell Q Rep (2009) 1.22
Clinical features of influenza A and B in children and association with myositis. J Microbiol Immunol Infect (2004) 1.16
Duration of protection provided by live attenuated influenza vaccine in children. Pediatr Infect Dis J (2008) 1.15
Comparison of influenza A and influenza B virus infection in hospitalized children. J Paediatr Child Health (2000) 1.14
Exploration of the emergence of the Victoria lineage of influenza B virus. Arch Virol (2006) 1.07
Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents. Clin Drug Investig (2006) 0.97
Influenza vaccination of schoolchildren and influenza outbreaks in a school. Clin Infect Dis (2011) 0.97
Clinical features of children infected with different strains of influenza B in southern Taiwan. Pediatr Infect Dis J (2008) 0.97
Decreased leukocytes and other characteristics of laboratory findings of influenza virus infections in children. J Microbiol Immunol Infect (2008) 0.93
Recommendations for the management of herpes zoster. Clin Infect Dis (2007) 4.33
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med (2015) 4.23
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis (2012) 3.94
Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med (2012) 2.77
Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med (2010) 2.73
Validation of a 3-factor scoring model for the Pittsburgh sleep quality index in older adults. Sleep (2006) 2.62
Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis (2012) 2.55
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin (2009) 2.51
Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain (2004) 2.15
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis (2009) 2.13
The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain (2007) 2.08
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine (2007) 2.01
Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2012) 1.98
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol (2010) 1.96
Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev (2003) 1.95
The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ (2010) 1.88
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2014) 1.81
Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc (2010) 1.76
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin (2011) 1.73
DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis (2007) 1.71
Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis (2008) 1.70
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2013) 1.69
The prevention and management of herpes zoster. Med J Aust (2008) 1.60
The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses (2010) 1.47
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin (2011) 1.46
Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. Arch Pediatr Adolesc Med (2004) 1.44
A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. J Med Virol (2009) 1.42
Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry (2008) 1.38
Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J (2006) 1.32
A prospective study of the herpes zoster severity of illness. Clin J Pain (2010) 1.22
Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. J Virol (2005) 1.19
VZV T cell-mediated immunity. Curr Top Microbiol Immunol (2010) 1.17
Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis (2010) 1.14
Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis (2013) 1.09
Nectin-1/HveC Mediates herpes simplex virus type 1 entry into primary human sensory neurons and fibroblasts. J Neurovirol (2005) 1.08
A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J (2009) 1.06
Human sensory neurons derived from induced pluripotent stem cells support varicella-zoster virus infection. PLoS One (2012) 1.05
Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine (2012) 1.05
Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine (2010) 1.04
Varicella vaccine in the United States: a decade of prevention and the way forward. J Infect Dis (2008) 1.02
Impairments in health functioning and sleep quality in older adults with a history of depression. J Am Geriatr Soc (2006) 1.01
Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics (2007) 1.00
Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine. Vaccine (2009) 0.98
Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2009) 0.97
Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob Agents Chemother (2002) 0.96
Major depressive disorder and immunity to varicella-zoster virus in the elderly. Brain Behav Immun (2011) 0.96
Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine (2007) 0.95
Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis (2005) 0.95
Persistent sleep disturbance: a risk factor for recurrent depression in community-dwelling older adults. Sleep (2013) 0.94
Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. Infect Dis Obstet Gynecol (2010) 0.89
Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. Clin Infect Dis (2013) 0.89
Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis (2007) 0.89
Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy. Vaccine (2013) 0.89
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine (2011) 0.88
Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother (2013) 0.87
Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis (2013) 0.87
Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2004) 0.87
Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis (2012) 0.87
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study. Hum Vaccin Immunother (2014) 0.86
Postentry events are responsible for restriction of productive varicella-zoster virus infection in Chinese hamster ovary cells. J Virol (2006) 0.86
Fractionation of neurons and satellite cells from human sensory ganglia in order to study herpesvirus latency. J Virol Methods (2002) 0.86
Resistance to antiretrovirals in HIV-infected pregnant women. J Clin Virol (2009) 0.85
Safety and tolerability of antiretrovirals during pregnancy. Infect Dis Obstet Gynecol (2011) 0.82
Workshop on immunizations in older adults: identifying future research agendas. J Am Geriatr Soc (2010) 0.82
Immune correlates of herpes zoster in HIV-infected children and youth. J Virol (2011) 0.82
Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin (2010) 0.81
Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Curr Opin Virol (2011) 0.80
T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines. AIDS Res Hum Retroviruses (2010) 0.80
Immune response to a refrigerator-stable zoster vaccine. Clin Vaccine Immunol (2009) 0.80
Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial. J Am Acad Dermatol (2010) 0.79
Factors that affect in vitro measurement of the susceptibility of herpes simplex virus to nucleoside analogues. J Clin Virol (2006) 0.79
GB virus C infection in children with perinatal human immunodeficiency virus infection. Pediatr Infect Dis J (2005) 0.79
Quadrivalent Ann Arbor strain live-attenuated influenza vaccine. Expert Rev Vaccines (2012) 0.79
Varicella-zoster virus-specific enzyme-linked immunospot assay responses and zoster-associated pain in herpes zoster subjects. Clin Vaccine Immunol (2012) 0.78
Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children. AIDS (2003) 0.78
Susceptibility of herpes simplex virus isolates to nucleoside analogues and the proportion of nucleoside-resistant variants after repeated topical application of penciclovir to recurrent herpes labialis. J Infect Dis (2003) 0.77
Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. Eur J Pain (2011) 0.77
Cytomegalovirus-specific cell-mediated immunity in HIV-infected children on HAART. AIDS Res Hum Retroviruses (2006) 0.77
Novel composite efficacy measure to demonstrate the rationale and efficacy of combination antiviral-anti-inflammatory treatment for recurrent herpes simplex labialis. Antimicrob Agents Chemother (2013) 0.75
Responder cell frequency estimation and binomial three-level nonlinear mixed effects model in limiting dilution assays. J Biopharm Stat (2005) 0.75
Herpes Simplex Virus and Varicella-Zoster Virus. Microbiol Spectr (2016) 0.75